Studies suggest that peptides like AOD 9604 may help battle excessive body fat and help test subjects keep their BMIs in the healthy range of 18.5 to 24.9, but is AOD-9604 a novel research component? Researchers have sought various innovative substances and solutions to combat this issue and come up with an answer.
Because of the decline in physical activity, maintaining a healthy calorie-intake-to-calorie-burn ratio has become more challenging. Also, aging is associated with a fall in the levels of many different natural hormones and peptides, which may cause problems, including weight gain and fatigue.
What is AOD 9604 Peptide?
AOD 9604 peptide is a synthetic version of a human hormone hypothesized to be useful in the context of obesity and to help test subjects lose weight, as the name would imply.
The little growth hormone produced by the body works to speed up the breakdown of fat stores, leading to weight loss. But among overweight subjects, even this fraction is repressed.
Human growth hormone (HGH) has been modified to generate a peptide consisting of the final 15 amino acids (177-191), which is referred to as GH Frag 177-191 or Anti-Obesity Drug (AOD) 9604. It comprises the C-terminal tyrosine residue and amino acids 177-191.
Unlike other anti-obesity compounds, research suggests that AOD 9604 may not work by artificially suppressing hunger and food absorption; instead, it has been purported to tackle obesity by producing a quicker metabolic rate.
AOD 9604 Peptide History
When trying to create compounds with anti-obesity properties like human growth hormone (hGH) without unwanted effects, Professor Frank Ng of Australia’s Monash University identified the AOD 9604 peptide in the 1990s.
The potential of AOD 9604 on raising metabolic rate, fat loss, lipolysis (the breakdown of fat), and high plasma glycerol has subsequently been the subject of much scientific study and experimentation, the results of which are addressed in further depth below.
Research suggests that human growth hormone (hGH) may be a synthetic fragment called AOD 9604 that may stimulate the pituitary gland to increase metabolic rate and facilitate rapid weight loss. In addition to its hGH-independent oxidative action, the AOD 9604 peptide is speculated to also stimulate lipolysis and anti-lipogenesis (fat production suppression).
Scientists proposed that this peptide may cause weight reduction without affecting hunger or insulin sensitivity negatively. Data from research suggests that AOD 9604 may cause fat cells in obese subjects to release fat and help the body burn off and retain less fat.
AOD 9604 Peptide Properties
The following are some of the peptide’s theorized properties, as they were suggested by research studies:
- It may reduce overall fat
- It may initiate fat breakdown in overstuffed adipose tissue.
- It may use a fat-regulating mechanism similar to that of natural growth hormone.
- It may stimulate fat breakdown and block fat synthesis.
- It may not waste muscle-mass quality.
- It may not lead to increased hunger (no impact on appetite).
- It may not affect either insulin sensitivity or IGF-1 levels
- It may contain healing potential for cartilage and bone, much to natural growth hormone.
Several studies have suggested that the AOD-9604 peptide, which contains a modified hGH, may significantly increase thermogenesis without promoting the synthesis of Insulin-like Growth Factor IGF 1.
It has been hypothesized that blood sugar levels aren’t the only thing high IGF 1 levels may affect; joints, heart, and liver can also suffer harm.
Since AOD 9604 does not increase the production of IGF 1, it may help in the context of conditions including osteoarthritis, osteoporosis, hypercholesterolemia, worn cartilage, and bone deterioration by preventing these effects of IGF 1. Unlike other anti-obesity agents, AOD 9604 has not been speculated to cause alterations in insulin sensitivity.
AOD 9604 Peptide and Intraperitoneal Research
AOD-9604 peptide was first tested in a 14-day, chronic intraperitoneal presentation in obese mice. Research models’ body mass index (BMI) and total body fat percentage (TBF) appeared to decrease after the intervention ended.
A higher concentration of ß3-AR cells, essential lipolytic receptors, was speculated in the adipose tissue, directly connected with these findings. Similarly to how hGH can raise the suppressed levels of lipolytic receptors in obese mice compared to lean animals, AOD 9604 peptide has been purported to do the same in overweight mice.
Additional investigations were conducted where AOD 9604 was given to mice with knocked-out lipolytic receptors to establish if the lipolytic potential of AOD 9604 was connected with the enhanced lipolytic receptor levels. The findings suggested that AOD 9604 appeared adequate, which was exciting in this circumstance.
In subsequent studies, the AOD 9604 peptide was implied to have lipolytic potential, as suggested by an uptick in metabolic rate and fat burned. Because of this, researchers proposed that AOD 9604 may successfully reduce fat regardless of the receptors, even if these investigations purported that AOD 9604 peptides may increase the expression of lipolytic receptors.
While increased ß3-AR expression was critical to AOD 9604’s chronic efficacy, the results of both the chronic and acute studies suggested that this receptor was not the only decider of the response. The peptide’s immediate impact appeared to rely heavily on oxidation and increased energy expenditure.
Conclusion
Investigations purport that an enhanced metabolic rate caused by the synthetic peptide AOD 9604 may stimulate lipolysis and anti-lipogenesis through an oxidation mechanism and a rise in lipolytic receptor expression, both of which are effects of hGH. Because of its similarity to human growth hormone, AOD 9604 has been studied extensively.
Researchers theorized that the AOD 9604 peptide may have exhibited other properties, such as regeneration capabilities. It is currently the subject of extensive research to realize its full potential in the context of conditions like osteoporosis and hypercholesterolemia.
You can click here if you are a researcher interested in buying AOD-9604 for your studies.
DISCLAIMER – “Views Expressed Disclaimer: Views and opinions expressed are those of the authors and do not reflect the official position of any other author, agency, organization, employer or company, including NEO CYMED PUBLISHING LIMITED, which is the publishing company performing under the name Cyprus-Mail…more
